By The Former Security Tablets In The Treatment Of Premenstrual Syndrome (liver Qi Stagnation), Clinical Observations,

Objective:To evaluate the efficacy and safety of Jingqianan tablet of treating premenstrual syndrome (PMS) in clinical trail, and to supply scientific evidences for the clinical usage of Jingqianan tablet. Methods:Random, double blind and double simulation and control method was adopted in this study. 87 cases of patients of PMS which had been diagnosed in our outpatient clinic were chosen and divided into the treatment group (Jingqianan tablet, n=66), and the control group (Xiaoyao pill, n=21). Both groups started about 14 days before menstrual period and ended until menses. A course contained three menstrual cycles. To observe the changes of clinical symptoms, sexual hormones and safety between the two groups and to compare each group between pretreatment and post-treatment. Results:(l)For 87 cases with the method, clinical cure rate and notable curative effect rate of the treatment group were 68.18%, the total rate of curative effect was 100%; there were no significant difference compared with the control group(P>0.05). (2)The treatment group could obviously ameliorate the correlate clinical symptoms (P<0.01), but there were no significant difference compared with the control group (P>0.05). (3)There were no significant difference between pretreatment and post-treatment in the level of E2, P, E2/P of the total 87 cases (P>0.05), but there was significant difference in the level of PRL (P<0.05). This showed Jingqianan tablet could regulate the level of PRL. (4) The toxic and adverse drug reaction was not observed. Conclusion:Jingqianan tablet is effective and safe in treatment of the liver qi invasion of PMS.